Fennec Pharma CSO receives 156-share stock grant

FENNEC PHARMACEUTICALS INC.

Rhea-AI Filing Summary

FENNEC PHARMACEUTICALS INC. (FENC) reported that Chief Strategy Officer Christiana Marie Cioffi acquired 156 common shares on 2026-08-31 through a grant, award, or other acquisition transaction at a stated price of $0.00 per share. A footnote explains these are shares released from restriction from shares awarded on 2025-03-28, bringing her direct holdings to 24,644 common shares.

Insider Trade Summary

Grant/Award: 156 shares

Grant/Award 1 txn

Insider Cioffi Christiana Marie

Role Chief Strategy Officer

Type	Security	Shares	Price	Value
Grant/Award	Common shares F1	156	$0.00	$0.00

Holdings After Transaction: Common shares — 24,644 shares (Direct)

Footnotes (1)

1. F1. Represents shares released from restriction from shares awarded 3/28/2025.

Key Figures

Common shares acquired: 156 common shares Transaction price per share: $0.00 per share Shares owned after transaction: 24,644 common shares +1 more

4 metrics

Common shares acquired 156 common shares Grant, award, or other acquisition on 2026-08-31

Transaction price per share $0.00 per share Reported for the 156 common shares acquired

Shares owned after transaction 24,644 common shares Direct holdings of Christiana Marie Cioffi following the transaction

Original award date for restricted shares 2025-03-28 Footnote states shares released from restriction from shares awarded on this date

Key Terms

Grant, award, or other acquisition, Common shares, shares released from restriction

3 terms

Grant, award, or other acquisition regulatory

"transaction_code_description: "Grant, award, or other acquisition""

Common shares financial

"security_title: "Common shares""

Common shares are the basic units of ownership in a company that give holders a claim on profits and a right to vote on key matters, like electing the board. Think of them as membership cards in a club: they let you share in successes and losses, but in a bankruptcy or liquidation they are paid after creditors and preferred shareholders, so their value can swing more and matters for assessing risk and potential return.

shares released from restriction financial

"Represents shares released from restriction from shares awarded 3/28/2025"

FAQ

What insider transaction did FENC report for Christiana Marie Cioffi?

FENNEC PHARMACEUTICALS INC. reported that Chief Strategy Officer Christiana Marie Cioffi had 156 common shares released from restriction on 2026-08-31, reported as a grant, award, or other acquisition at a stated price of $0.00 per share.

How many FENC shares does Christiana Marie Cioffi own after this transaction?

After the reported transaction, Christiana Marie Cioffi directly owns 24,644 common shares of FENNEC PHARMACEUTICALS INC., according to the Form 4 data.

Was the FENC insider transaction a market purchase or a share grant?

The Form 4 classifies the transaction as a grant, award, or other acquisition (code A), not a market purchase. A footnote states the 156 shares represent shares released from restriction from shares awarded on 2025-03-28.

What price is reported for the FENC insider share acquisition?

The Form 4 reports a transaction price of $0.00 per share for the 156 common shares acquired by Christiana Marie Cioffi, consistent with a grant, award, or other acquisition rather than an open-market purchase.

Does the FENC Form 4 mention a Rule 10b5-1 trading plan?

No. The filing’s Rule 10b5-1 checkbox is unchecked (aff_10b5_one is false), and there is no footnote stating that the transaction was made under a Rule 10b5-1 or similar trading plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/31/2026 - 08:13 PM Accepted by SEC EDGAR 08/31/2026 - 08:12 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cioffi Christiana Marie

(Last) (First) (Middle)

C/O FENNEC PHARMACEUTICALS, INC.

PO BOX 13628, 68 TW ALEXANDER DRIVE

(Street)

RESEARCH TRIANGLE PARK NORTH CAROLINA 27709

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
FENNEC PHARMACEUTICALS INC. [ FENC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Strategy Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/31/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common shares(1)	08/31/2026		A		156	A	$0	24,644	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares released from restriction from shares awarded 3/28/2025.

	/s/ Christiana Cioffi	08/31/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)